Life sciences briefing: Wednesday, Feb. 13, 2008
TODAY’S HEADLINES:
Molecular-diagnostics maker Atlas Genetics gets £2.1M (MS Word release)
One-man shop Paloma Pharma takes in $5M for eye, cancer drugs (VentureWire)
Israel’s Optimata receives $1.5M for simulations to rescue failed drugs (release)
Centrose raises $1.3M for sugar-modified drugs (Milwaukee Journal-Sentinel)
Halyard buys healthcare-compliance adviser HCPro from Riverside (release)
RiverRock… Continue Reading
Life sciences briefing: Friday, Nov. 9, 2007
Featured companies: Antisense Pharma, Arteriocyte, Excelimmune, Fluxion Biosciences
UPDATED: Expanded items on Antisense Pharma, Arteriocyte, and Excelimmune.
Antisense Pharma raises €27M for cancer drugs — Munich’s Antisense Pharma, a biotech developing gene-silencing drugs against cancer, raised €27 million ($38 million) in a fourth funding round. The company’s PDF release… Continue Reading
Life sciences briefing: Monday, Oct. 22, 2007
Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas, High-Throughput Genomics, Orchid Cellmark, ReliaGene Technologies, SarCode, TransMolecular, VisEn Medical
UPDATED: Expanded items on SarCode, Celldex/Avant and Ablynx.
UPDATE REDUX: Added items on BioForm Medical, High-Throughput Genomics and Orchid Cellmark/ReliaGene.
San Francisco’s SarCode draws down $7M for inflammation drugs — The… Continue Reading
Biotech financing: Not everyone gets a turn at the firehose
Every trend has its counterexamples, and the rush of venture funding into biotechnology is no exception.
VentureWire reports today (subscription required) on the case of Sequella, a small Rockville, Md., biotech working on new therapies for drug-resistant tuberculosis (whose bacterium is pictured at left). The… Continue Reading